Our group is mainly focused on evaluate the potential of using cell therapy in cardiovascular diseases, mainly focused on atherosclerosis, with endothelial progenitor cells and regulatory T cells. We aim to understand how these cells react, at molecular and functional level, under pathological conditions, in order to modulate them and potentiate theri regenerative and modulatory role against the inflammatory and ischemic conditions, as in atherosclerosis. We perform assays in vitro, at cellular level, and also in vivo assays administrating these cells to the CLI mice to test the response of the cells and also the ischemic tissue changes related. We also collaborate with Rexgenero Biosciences, performing cell biodistribution assays, to identify cell localization within the injured tissues or in other organs. Finally, we are currently performing an study to identify potential markers in dyslipemic/atherosclerotic patients by proteomic strategies, in order to be able to define a protein panel for early diagnosis.
Cell therapy in Critical limb ischemia
Proteomics in the search of cardiovascular research related biomarkers
Cell therapy in Atherosclerosis
- Proteomic tools for the identification of differential proteins, as well as label-free quantitative approaches by mass spectrometry (MaxQuant, Proteome-Discoverer, Perseus). Software for functional classification: Ingenuity, String, cytoskape....
- Cell culture, isolation, culture and characterization of primary cells (Tcell, EPC), and cell lines. Flow Citometry and Fluorescence Microscopy
- Immunohistochemistry and immunocytochemistry
-RT-qPCR, western-blot, ELISA tools for expression analysis
- Animal research: Femoral ligation, blood flow measurements, Critical limb ischemia model, cell biodistribution assays